Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.

There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

UFS Doctors make History in South Africa
2011-07-14

 

New aortic valve

Three members of our Faculty of Health Sciences made history by being the first to implant a special new aortic valve in South Africa. 
 
In a combined effort, the Departments of Cardiology, Pediatric Cardiology and Cardiothoracic Surgery did the first Medtronic CoreValve implant in South Africa on a patient in Universitas Academic Hospital. 
 
With the support of hospital management and the Medtronic company, Prof. Hennie Theron, Prof. Stephen Brown and Dr JP Theron of the Faculty of Health Sciences, with the assistance of Dr Jean-Claude Laborde, performed the operation early on Wednesday morning, 06 July 2011.
 
The advantage of this new valve is that it can be implanted percutaneously through a catheter from the groin. This eliminates the need for invasive surgery.
 
The valve is made from porcine pericardium (tissue derived from pigs) and is mounted on an expandable stent, which is threaded along an artery, until it reaches its desired position. Prof. Theron says the valve is especially useful in older patients who suffer from aortic valve disease and pose a high surgical risk. Furthermore, the use of this valve greatly reduces hospitalisation time, in comparison to traditional surgery.
 
“One patient already received an implant this morning and we hope to finish 2 more today,” Prof. Brown said, emphasizing the swiftness and efficiency of the new valve implanting process.
 
“It is a complex procedure, but this service can in future be offered to all patients in the public and private sectors of the Free State. It is heartwarming that the academic complex can take the lead in this modern, high-tech therapy.”
 
For more information on the procedure, please contact Prof. Theron at 051 4053428.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept